Recipharm AB Provides access to Asmasal Clickhaler Dossier for Vectura plc Chinese Market Approval
Recipharm AB is pleased to announce that it is working with Vectura Group plc to provide access to its licence for the regulatory dossier of Asmasal for the Chinese regulatory authorities as part of the Chinese market approval process. The regulatory submission will be led by Vectura’s recently announced new strategic joint venture, Tianjin Kinnovata Pharmaceutical Company Limited (Kinnovata), (www.vectura.com/media/
Asmasal Clickhaler is a dry powder inhaler that contains the active ingredient salbutamol, which is used in conditions where there is narrowing of the airways, such as asthma or chronic obstructive pulmonary disease (COPD). Vectura’s Clickhaler device allows the active to be delivered directly into the lungs. Recipharm currently supply the product to markets in the UK and France.
An application for the import of Asmasal Clickhaler (salbutamol) has been filed with the Chinese State Food and Drug Administration (SFDA) and this collaboration will see Recipharm manufacturing finished product for Kinnovata and the Chinese market. Recipharm will also provide technical assistance to Kinnovata to transfer the manufacturing know-how to Kinnovata facilities in China.
“We are happy to be involved with Vectura’s joint venture in the Chinese pharma market and we believe that we can contribute to this, not just from providing access to the product but also from providing services to Kinnovata until its local manufacturing is up and running,” says Carl-Johan Spak, Executive Vice President, Development & Technology at Recipharm.
China’s pharmaceutical market, is growing at a rapid rate and is expected to reach $40 billion in market size in 2020, making it the 3rd largest pharmaceutical market worldwide. Recent estimates suggest the overall incidence of asthma in China is approximately 2.0%[i];of a patient population of more than 25 million people. COPD is an even bigger challenge, with approximately 42 million people suffering in China, and forecasts estimate that this number will increase to nearly 56 million by 2021[ii].. The agreement between Recipharm and Vectura provides an opportunity for a well established product to be used to help fill the need for affordable treatment in China.
References
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance